GET DAILY SIGNALSEstablishment Labs (ESTA) Delivers +33.9% Revenue Growth and First Positive Free Cash Flow
Key Takeaways
- Revenue rose 33.9% year over year to $72.0 million, ahead of the roughly $66.6 million consensus estimate.
- GAAP net loss narrowed to $10.7 million, or $0.35 per share, versus a loss of $0.38 per share a year earlier.
- U.S. revenue climbed 119% to $26.0 million, while revenue outside the United States (OUS) grew 9.7% to $46.0 million.
- Adjusted EBITDA reached $6.4 million, and the company posted its first quarter of positive free cash flow at $5.1 million.
- Management raised full-year 2026 revenue guidance to more than $274 million, up from its prior range of $269 million to $271 million.
- Adjusted gross margin was 70.8%, and the company guided full-year adjusted gross margin to approximately 70.7%.
- For more details, explore Major News, Today's Price Move, Price Targets, and Forecast pages.
- Discover additional market ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
Establishment Labs Holdings is a Costa Rica-based medical technology company focused on women's health, breast aesthetics, and breast reconstruction, best known for its Motiva implant portfolio. Its third-quarter report matters because it tests whether the company can convert rapid U.S. market-share gains into improving profitability and cash generation. Heading into the print, investors were watching top-line momentum, gross margin trajectory, and the path toward positive free cash flow. The company entered the quarter having raised guidance in consecutive periods, and the U.S. launch of Motiva and the Preservé minimally invasive platform remained the central growth story. Results delivered record-scale revenue growth and a long-awaited cash-flow milestone, even as one-time charges pressured the reported bottom line.
Reported Results
For the third quarter ended September 30, 2026, Establishment Labs reported revenue of $72.0 million, an increase of 33.9% from $53.8 million in the prior-year period and above the consensus estimate of approximately $66.6 million. U.S. revenue surged 119% to $26.0 million, representing 36.1% of total revenue, while revenue outside the United States rose 9.7% to $46.0 million. The minimally invasive platform generated about $9 million in revenue, up 124% year over year.
GAAP net loss narrowed to $10.7 million, or $0.35 per share, compared with a loss of $11.1 million, or $0.38 per share, a year earlier. The per-share result came in below the consensus estimate of a $0.27 loss, driven largely by below-the-line interest expense and one-time litigation, restructuring, and inventory charges. GAAP gross margin was 69.1%, while adjusted gross margin improved to 70.8%, up 70 basis points year over year on a favorable U.S. and minimally invasive product mix. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Adjusted EBITDA increased to $6.4 million, or 8.9% of revenue, from $1.2 million in the prior-year quarter. The company generated $7.7 million in operating cash flow and $5.1 million in free cash flow, marking its first positive free-cash-flow quarter. Management also raised full-year 2026 revenue guidance to more than $274 million and reiterated an expectation for roughly 25% revenue growth in 2027.
Market Reaction and Investor Sentiment
The market's focus was split between the company's accelerating U.S. growth and the headline earnings-per-share miss. While revenue beat expectations by roughly 8%, the $0.35 per-share loss fell short of the consensus $0.27 loss, reflecting interest expense on the company's note payable and one-time litigation, restructuring, and inventory-related charges. Investors appeared to weigh the quality of the operating results more heavily, as adjusted EBITDA expanded, operating leverage improved, and the company delivered its first positive free-cash-flow quarter. The third consecutive full-year revenue guidance increase, along with a reaffirmed expectation for about 25% revenue growth in 2027, reinforced the view that demand momentum remains intact. Sentiment remains balanced against thinner profitability in OUS distributor channels and the company's relatively lean balance sheet.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will likely track whether Establishment Labs can sustain its U.S. adoption momentum while converting that growth into durable profitability and cash generation. Management pointed to an 85% quarter-over-quarter reorder rate among U.S. accounts and more than 2,100 active accounts, suggesting utilization within the existing surgeon base is becoming the key growth lever.
Regulatory and product milestones will also be closely watched. The October FDA approval of additional Motiva implant sizes is expected to be commercially available before year-end, and management is working toward a reconstruction approval targeted for late 2026 or early 2027. The company also plans to expand sizes for its Mia and Preservé minimally invasive products globally.
On the financial side, the full-year adjusted gross margin guidance of approximately 70.7% reflects a higher mix of lower-margin OUS distributor sales, a dynamic worth monitoring. The company reiterated full-year adjusted operating expense guidance of $195 million to $200 million. With the balance sheet still carrying a substantial note payable against $75.8 million in cash, sustained free-cash-flow generation will remain a focal point for investors assessing the company's path toward self-funding growth. From what I see, the balance between U.S. momentum and OUS margins will be worth following closely.
Using AI Tools in My Research Workflow
In my analysis of names like ESTA, I regularly turn to Tickeron’s AI-powered tools to scan for patterns and compare fundamentals across the sector. The AI Screener stands out for its ability to filter thousands of stocks and ETFs by technical indicators, performance metrics, and AI-driven signals. It helps surface comparable opportunities efficiently and supports a more structured approach to building watchlists. I find it particularly useful when evaluating how a company’s momentum stacks up against peers before diving deeper into the numbers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ESTA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ESTA turned positive on October 20, 2026. Looking at past instances where ESTA's MACD turned positive, the stock continued to rise in 45 of 53 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ESTA's RSI Oscillator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on ESTA as a result. In 79 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
ESTA moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where ESTA advanced for three days, in 239 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for ESTA moved below the 200-day moving average on October 08, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
ESTA broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ESTA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ESTA's P/B Ratio (94.356) is very high in comparison to the industry average of (3.824). P/E Ratio (-53.866) is within average values for comparable stocks, (1.677). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (8.749) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ESTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medical products
Industry MedicalNursingServices
Advertisement